Skin Cancer Awareness Month: TILs Offer New Hope in Advanced Melanoma
Source: Targeted Oncology, May 2024
Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.
In February 2024, the FDA approved lifileucel (LN-44), a tumor infiltrating lymphocyte (TIL) therapy for advanced melanoma. This is the first of its kind for solid tumors and represents a significant step forward for melanoma treatment.
TIL therapy harnesses a patient’s own immune system to fight cancer. Doctors extract immune cells from a patient’s tumor, grow them in a lab, and then reinfuse them back into the patient. These TILs are specifically targeted to fight the patient’s unique cancer cells.